Allergan : FDA Oks 3 Extended Release Products Equivalent To Mucinex, Mucinex DM

(RTTNews) - Allergan plc (AGN) and its partner Perrigo Company plc (PRGO) announced that Allergan has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Applications for three Mucinex equivalent products.

They are Mucinex DM Regular Strength (guaifenesin 600mg and dextromethorphan 30mg); Mucinex DM Maximum Strength (guaifenesin 1200mg and dextromethorphan 60mg); Mucinex Maximum Strength (guaifenesin 1200mg).

Perrigo will begin shipments of the products to its retail and wholesale customers in the U.S in time for the 2016 cough and cold season. These products will be packaged and marketed as store brands which will give consumers high quality, value alternatives to these Mucinex extended-release products.

Mucinex Maximum Strength is an expectorant indicated to relieve chest congestion and thin and loosen mucus. Sales for the last twelve months were $73 million.

Mucinex DM Regular and Maximum Strengths are expectorants indicated to control coughs and thin and loosen mucus. Mucinex DM Regular and Maximum Strengths sales for the last twelve months were $67 million and $104 million, respectively.